| 货号 | HB185076 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 同种型 | IgG1-kappa |
|---|
| 克隆号 | BI 836858 |
|---|
| 生物活性 | BI-836858 (10 ug/mL; 30 min) mediates specific ADCC activity against primary AML blasts [1]. BI-836858 (2 ug/mL; 4 h) mediates NK cell-dependent ADCC activity against CD33-positive HL60 cells [2]. BI-836858 (2 ug/mL; 48 h) blocks the CD33-mediated inhibitory signaling pathway in MDS bone marrow cells and reduces the expression of IL-10 and TGFβ [2]. BI-836858 (2 ug/mL) specifically blocks CD33 (S100A9)-mediated ROS production in U937 cells, healthy PBMCs, and primary MDS BM HSPCs [2]. BI-836858 (2 ug/mL; 14 days) restores the hematopoietic colony-forming capacity in ex vivo cultures of primary MDS bone marrow specimens [2]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 靶标 | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P20138 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | BI-836858, BI836858, BI836858 |
|---|
| 背景 | Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 106113432. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 113202123. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 155973237. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 102069558. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798 |
|---|
| 文献 | 1. Gopalakrishnan B, et al. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018;9(11):9706-9713. Published 2018 Jan 3. [HB185076]
2. Eksioglu EA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180. [HB185076] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
|---|
